The nation of Zimbabwe has rejected a significant US health deal worth 367 million US dollars (£272m) spanning five years because of the United States' insistence on sensitive data.
This rejection came to light following a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson later explained that the United States was requesting genetic material for scientific study and profit but was unwilling to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for continued negotiations to secure a agreement agreeable to all parties so the nation's critical HIV programme can proceed.
Broader Background
Zimbabwe's decision comes after a similar case in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information over an extended period, with no corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our people if a new health crisis arise."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending structures previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future collaboration could be designed in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that negotiations must proceed given that much of the nation's HIV programmes depended on foreign aid.
"Where specific concerns exist, including those involving information security or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
This impasse emphasises the continuing challenges between receiving vital international aid and protecting national sovereignty in an increasingly data-driven world.